Arbutus Biopharma
ABUS
112 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 7 closing their positions.
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
49% more capital invested
Capital invested by funds: $144M → $215M (+$71M)
18% more call options, than puts
Call options by funds: $4.66M | Put options by funds: $3.94M
17% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 29
13% more funds holding
Funds holding: 99 → 112 (+13)
8.96% more ownership
Funds ownership: 42.28% → 51.24% (+9%)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$17.1M |
| 2 |
WCM
Whitefort Capital Management
New York
|
+$2.55M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$1.49M |
| 4 |
CC
Centiva Capital
New York
|
+$684K |
| 5 |
State Street
Boston,
Massachusetts
|
+$461K |
Top Sellers
| 1 |
JFG
Jefferies Financial Group
New York
|
-$537K |
| 2 |
FCM
FourWorld Capital Management
New York
|
-$492K |
| 3 |
KC
Kepos Capital
New York
|
-$316K |
| 4 |
Citigroup
New York
|
-$230K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$199K |
ABUS Hedge Fund Activity: Q4 2023 in Review
112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2023, worth a combined $215M — up 49% from $144M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ABUS positions and 7 closed out — a net gain of 14 holders — while 34 added to existing stakes and 29 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $17.1M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $537K sold.
- 112 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2023, up from 99 in Q3 2023.
- Funds reported $215M of Arbutus Biopharma stock for Q4 2023, up 49% quarter-over-quarter.
- 21 funds opened new Arbutus Biopharma positions in Q4 2023 and 7 closed out, a net change of +14 holders.
- The largest Arbutus Biopharma buyer in Q4 2023 was Morgan Stanley, an estimated $17.1M added.
- The largest Arbutus Biopharma seller in Q4 2023 was Jefferies Financial Group, an estimated $537K sold.
Based on aggregated 13F filings for Q4 2023.